Last reviewed · How we verify
Nystatin 100.000 units
Nystatin 100.000 units is a Small molecule drug developed by University of Sao Paulo. It is currently FDA-approved. Also known as: Nystatin.
At a glance
| Generic name | Nystatin 100.000 units |
|---|---|
| Also known as | Nystatin |
| Sponsor | University of Sao Paulo |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nystatin 100.000 units CI brief — competitive landscape report
- Nystatin 100.000 units updates RSS · CI watch RSS
- University of Sao Paulo portfolio CI
Frequently asked questions about Nystatin 100.000 units
What is Nystatin 100.000 units?
Nystatin 100.000 units is a Small molecule drug developed by University of Sao Paulo.
Who makes Nystatin 100.000 units?
Nystatin 100.000 units is developed and marketed by University of Sao Paulo (see full University of Sao Paulo pipeline at /company/university-of-sao-paulo).
Is Nystatin 100.000 units also known as anything else?
Nystatin 100.000 units is also known as Nystatin.
What development phase is Nystatin 100.000 units in?
Nystatin 100.000 units is FDA-approved (marketed).
Related
- Manufacturer: University of Sao Paulo — full pipeline
- Also known as: Nystatin
- Compare: Nystatin 100.000 units vs similar drugs
- Pricing: Nystatin 100.000 units cost, discount & access